Home » Topics » Regulatory » EMA

EMA
RSS

CHMP recommends E.U. approval of Gazyvaro for treatment of previously treated follicular lymphoma

May 3, 2016

EMA committee backs marketing authorization for Enzepi

May 2, 2016

CHMP backs approval of Imbruvica in CLL

May 2, 2016

Avibactam/ceftazidime gets positive opinion from CHMP

May 2, 2016

Daclizumab recommended for approval in E.U.

May 2, 2016

Gilead's MAA for Odefsey single tablet regimen receives positive opinion for the treatment of HIV

May 2, 2016

EMA committee extends safety review of direct-acting antivirals

April 18, 2016

EMA committee recommends that Alprolix maintains orphan drug designation

April 11, 2016

Bristol-Myers Squibb's Opdivo approved in new indication in E.U.

April 7, 2016

Halaven receives positive CHMP opinion on new indication in Europe

April 6, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...